The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized, double-blind, placebo-controlled proof of concept study of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who experience response or stabilization during first-line docetaxel chemotherapy.
Karim Fizazi
Consultant or Advisory Role - Ipsen
Axel Heidenreich
Consultant or Advisory Role - Astellas Pharma; Bayer; Ferring; Ipsen; Janssen-Cilag; Sanofi ; Takeda
Honoraria - Astellas Pharma; Bayer; Ferring; Ipsen; Janssen-Cilag; Sanofi ; Takeda
Research Funding - Astellas Pharma; Sanofi
Gedske Daugaard
No relevant relationships to disclose
Joaquim Bellmunt
Consultant or Advisory Role - Ipsen
Nathalie Germann
Employment or Leadership Position - Ipsen
Eric Chetaille
Employment or Leadership Position - Ipsen
Stock Ownership - Ipsen
Honoraria - Ipsen